Evolution of resistance mutations during low-level viral replication in HIV-1-infected patients treated with zidovudine/lamivudine/abacavir as a first-line regimen

Antiviral Therapy

Volumn 12, Issue 1, 2007, Pages 25-30

  Stürmer, Martin ^a   Dauer, Brenda ^a   Moesch, Manfred ^a   Haberl, Annette ^a   Mueller, Axel ^a   Locher, Leo ^b   Knecht, Gaby ^c   Hanke, Nora ^a   Doerr, Hans W ^a   Staszewski, Schlomo ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b HIV Speciality Practice   (Germany)

^c Internistisches Facharztzentrum   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; THYMIDINE;

ARTICLE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MUTATION; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT OUTCOME; VIREMIA; VIROLOGY; VIRUS LOAD; VIRUS REPLICATION; VIRUS RESISTANCE; VIRUS STRAIN;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; DIDEOXYNUCLEOSIDES; DNA, VIRAL; DRUG COMBINATIONS; DRUG MONITORING; DRUG RESISTANCE, VIRAL; FOLLOW-UP STUDIES; GENOTYPE; GERMANY; HIV INFECTIONS; HIV-1; HUMANS; LAMIVUDINE; METHIONINE; MUTATION; REVERSE TRANSCRIPTASE INHIBITORS; THYMIDINE; TIME FACTORS; TREATMENT FAILURE; VALINE; VIRAL LOAD; VIRUS REPLICATION; ZIDOVUDINE;

EID: 33847405664     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Pozniak A, Gazzard B, Anderson J, et al. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy. HIV Med 2003; 4 Suppl 1:1-41.
2. Salzberger B, Marcus U, Vielhaber B, et al. German-Austrian Recommendations for the Antiretroviral Therapy of HIV-infection (Status May 2004). Eur J Med Res 2004; 9:491-504.
3. Yeni PG, Hammer SM, Hirsch MS, et al. Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel. JAMA 2004; 292:251-265.
4. Gartland M. AVANTI 3: a randomized, double-blind trial to compare the efficacy and safety of lamivudine plus zidovudine versus lamivudine plus zidovudine plus nelfinavir in HIV-1-infected antiretroviral-naive patients. Antivir Ther 2001; 6:127-134.
5. Gulick RM, Mellors JW, Havlir D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997; 337:734-739.
6. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med 1997; 337:725-733.
7. Podzamczer D, Ferrer E, Consiglio E, et al. A randomized clinical trial comparing nelfinavir or nevirapine associated to zidovudine/lamivudme in HIV-infected naive patients (the Combine Study). Antivir Ther 2002; 7:81-90.
8. Robbins GK, De Gruttola, V, Shafer RW, et al. Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection. N Engl J Med 2003; 349:2293-2303.
9. Staszewski S, Morales-Ramirez J, Tashima KT, et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. N Engl J Med 1999; 341:1865-1873.
10. van Leeuwen R, Katlama C, Murphy RL, et al. A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patients. AIDS 2003; 17:987-999.
11. Carr A, Samaras K, Chisholm DJ, Cooper DA. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet 1998; 351:1881-1883.
12. Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998; 12:F51-F58.
13. Miller KD, Jones E, Yanovski JA, Shankar R, Feuerstein I, Falloon J. Visceral abdominal-fat accumulation associated with use of indinavir. Lancet 1998; 351:871-875.
14. Mulligan K, Grunfeld C, Tai VW, et al. Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection. J Acquir Immune Defic Syndr 2000; 23:35-43.
15. Walli R, Herfort O, Michl GM, et al. Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1-infected patients. AIDS 1998; 12:F167-F173.
16. Matheron S, Descamps D, Boue F, et al. Triple nucleoside combination zidovudine/lamivudine/abacavir versus zidovudine/lamivudine/ nelfinavir as first-line therapy in HIV-1-infected adults: a randomized trial. Antivir Ther 2003; 8:163-171.
17. Staszewski S, Keiser P, Montaner J, et al. Abacavir-lamivudine- zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: A randomized equivalence trial. JAMA 2001; 285:1155-1163.
18. Vibhagool A, Cahn P, Schechter M, et al. Triple nucleoside treatment with abacavir plus the lamivudine/zidovudine combination tablet (COM) compared to indinavir/COM in antiretroviral therapy-naive adults: results of a 48-week open-label, equivalence trial (CNA3014). Curr Med Res Opin 2004; 20:1103-1114.
19. Gulick RM, Ribaudo HJ, Shikuma CM, et al. Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. N Engl J Med 2004; 350:1850-1861.
20. Ait-Khaled M, Rakik A, Griffin P, et al. Mutations in HIV-1 reverse transcriptase during therapy with abacavir, lamivudine and zidovudine in HIV-1-infected adults with no prior antiretroviral therapy. Antivir Ther 2002; 7:43-51.
21. Sturmer M, Berger A, Doerr HW. Modifications and substitutions of the RNA extraction module in the ViroSeq HIV-1 genotyping system version 2: effects on sensitivity and complexity of the assay. J Med Virol 2003; 71:475-479.
22. Sturmer M, Berger A, Preiser W. HIV-1 genotyping: comparison of two commercially available assays. Expert Rev Mol Diagn 2004; 4:281-291.
23. Liu TF and Shafer RW. Web resources for HIV type 1 genotypic-resistance test interpretation. Clin Infect Dis 2006; 42:1608-1618.
24. Johnson VA, Brun-Vezinet F, Clotet B, et al. Update of the drug resistance mutations in HIV-1: Fall 2005. Top HIV Med 2005; 13:125-131.
25. Whitcomb JM, Parkin NT, Chappey C, Hellmann NS, Petropoulos CJ. Broad nucleoside reverse-transcriptase inhibitor cross-resistance in human immunodeficiency virus type 1 clinical isolates. J Infect Dis 2003; 188:992-1000.
26. Eron JJ, Benoit SL, Jemsek J, et al. Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. North American HIV Working Party. N Engl J Med 1995; 333:1662-1669.
27. Maguire M, Gartland M, Moore S, et al. Absence of zidovudine resistance in antiretroviral-naive patients following zidovudine/lamivudine/ protease inhibitor combination therapy: virological evaluation of the AVANTI 2 and AVANTI 3 studies. AIDS 2000; 14:1195-1201.
28. Campbell TB, Shulman NS, Johnson SC, et al. Antiviral activity of lamivudine in salvage therapy for multidrug-resistant HIV-1 infection. Clin Infect Dis 2005; 41:236-242.